Actinium Pharmaceuticals Brief Analyst Report by Small Cap IR: Targeting a Killer
NEW YORK, Oct. 16, 2014 /PRNewswire/ -- Analyst Report by Small Cap IR. Actinium Pharmaceuticals, Inc. (NYSE: ATNM) – According to the World Health Organization, over 14 million new cases of cancer are reported each year, and cancer cases are expected to surge 57% worldwide over the next 20 years. The fastest growing hospital treatment in the United States to treat this disease is Hematopoietic Stem Cell Transplantation; the transplantation of multipotent hematopoietic stem cells derived from bone marrow, peripheral blood, or umbilical cord blood.
Actinium Pharmaceuticals is a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. The Company's products are based on patented technology co-developed with Memorial Sloan Kettering Cancer Center (MSKCC) for combining monoclonal antibodies (mAb) for targeting specific types of cells with alpha emitting radioisotopes. The company has developed drugs for treating leukemia, metastatic colorectal and prostate cancers, antiangiogenesis (prevention of blood supply to and growth of many solid cancers), and bone marrow ablation (a treatment for leukemias, lymphomas and multiple myeloma).
A brief analyst report on ATNM that includes recent events, stock's technical outlook and analyst comments can be viewed by using the following link at no cost:
http://bit.ly/-ATNM-AnalystReport
About Small Cap IR
Once you have read our reports written by financial analysts you will understand that we make every effort to provide informative equity research reports for interested parties.
3rd party financial analysts provide a straightforward assessment of the profiled company and have pledged to remain free of influence when writing research reports. They include stocks traded in the NYSE, NASDAQ, and OTCBB exchanges.
Forward-Looking Disclaimer
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.
Compliance Procedure
Content is researched, written and reviewed on a best-effort basis by a 3rd party research analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. We do not engage in high frequency trading.
A full disclaimer can be found by viewing the analyst report.
If you wish to have a company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected]. For any urgent concerns or inquiries please contact us at [email protected].
Contact: [email protected]
SOURCE Small Cap IR
Share this article